糖尿乐胶囊联合吡格列酮治疗2型糖尿病的临床研究

目的 探讨糖尿乐胶囊联合盐酸吡格列酮片治疗2型糖尿病的临床疗效。方法 选取2020年4月—2023年3月华北医疗健康集团峰峰总医院收治的100例2型糖尿病患者，将100例患者随机分为对照组（50例）和治疗组（50例）。对照组患者口服盐酸吡格列酮片，2片/次，1次/d。治疗组患者在对照组患者的基础上口服糖尿乐胶囊，4粒/次，3次/d。两组患者持续治疗3个月。比较两组临床效果、临床症状消失时间、血糖指标和血清指标。结果 治疗后，治疗组的总有效率为94.00%，对照组的总有效率为78.00%，组间差异显著（P＜0.05）。治疗后，治疗组多饮、多尿、乏力消失时间均明显短于对照组（P＜0.05）。治疗后，两组的空腹血糖（FPG）、餐后血糖（PPG）、糖化血红蛋白（HbA1c）均低于治疗前（P＜0.05），且治疗组血糖指标较对照组更低（P＜0.05）。治疗后，两组的血清中性粒细胞与淋巴细胞比率（NLR）、血清肾损伤分子-1（KIM-1）、中性粒细胞明胶酶相关载脂蛋白（NGAL）水平低于治疗前（P＜0.05）；治疗组的血清NLR、KIM-1、NGAL水平低于对照组（P＜0.05）。结论 糖尿乐胶囊联合盐酸吡格列酮片可提高2型糖尿病的疗效，促进症状好转，进一步降低血糖，有助于降低肾损伤。

Clinical study on Tangniaole Capsules combined with pioglitazone in treatment of type 2 diabetes mellitus

Objective To investigate the clinical efficacy of Tangniaole Capsules combined with Pioglitazone Hydrochloride Tablets in treatment of type 2 diabetes mellitus. Methods Patients (100 cases) with type 2 diabetes mellitus in Fengfeng General Hospital of North China Medical and Health Group from April 2020 to March 2023 were randomly divided into control and treatment groups, and each group had 50 cases. Patients in the control group were po administered with Pioglitazone Hydrochloride Tablets, 2 tablets/time, once daily. Patients in the treatment group were po administered with Tangniaole Capsules on the basis of the control group, 4 grains/time, three times daily. Patients in two groups were treated for 3 months. The clinical efficacies, main symptom resolution time, blood glucose indexes, and serum indexes in two groups were compared. Results After treatment, the total effective rate was 94.00% in the treatment group and 78.00% in the control group, with significant difference between groups (P < 0.05). After treatment, the disappearance time of polydipsia, polyuria, and fatigue in the treatment group was significantly shorter than those in the control group (P < 0.05). After treatment, FPG, PPG, and HbA1c in two groups were lower than those before treatment (P < 0.05), and the blood glucose index in the treatment group was lower than those in the control group (P < 0.05). After treatment, the serum levels of NLR, KIM-1, and NGAL in two groups were lower than those before treatment P < 0.05), and the levels of NLR, KIM-1 and NGAL in the treatment group were lower than those in the control group (P < 0.05). Conclusion Tangniaole Capsules combined with Pioglitazone Hydrochloride Tablets can improve the curative effect of type 2 diabetes mellitus, further reduce blood sugar, promote the improvement of symptoms, and help reduce kidney damage.